- MINDCURE President and CEO Kelsey Ramsden will participate in, and has already attended multiple industry conferences throughout December
- Participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics
- Company remains focused on promoting healing and improving mental health via digital therapeutics technology and psychedelic compounds research
- Company reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that 12,472 registered mental health facilities treatment facilities could benefit from the company’s proprietary digital therapeutics technology, iSTRYM
- The global digital therapeutics market is valued at $3.4 billion and is projected to reach $13.1 billion by 2026, primarily driven by the growing need for control over healthcare costs and the rising focus on preventative health opportunities
Life sciences company
Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) a leader in advanced proprietary technology and research for psychedelics, is rounding out 2021 by participating in the Life Sciences Investor Forum, a virtual investor conference that provides a fully interactive forum where publicly-traded companies can meet and present directly to investors. President and CEO of MINDCURE, Kelsey Ramsden, will be presenting virtually during the Life Sciences Investor Forum – which will be available archived on the conference’s website after the event has concluded (
https://ibn.fm/q34CM). The virtual forum will take place on December 16, 2021, with MINDCURE presenting at 11:30 AM EST.
Ms. Ramsden has already presented at three other industry events thus far in December – including the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, the Psychedelics Now Virtual Conference on December 8, and #CanndoraConnect: Women in Psychedelics Conference on December 8.
The presentation at H.C. Wainwright will be available to the public for 90 days following the conference, on MINDCURE’s investor relations website, and requires registration (
https://ibn.fm/dzpnW). At the Psychedelics Now Virtual Conference, Ms. Ramsden participated in the “Road to Monetization” webcast panel, which is currently available online (
https://ibn.fm/WEZe4). Registration is required to view the panel.
Ms. Ramsden’s participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics. MINDCURE expects growing job opportunities in the industry, as the psychedelics sector is expanding. Research cited by the company indicates that the global functional mushroom market will reach a value of $37 billion by 2025, up from the $23 billion value it held in 2019 (
https://ibn.fm/Cx5M8).
The company’s focus on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide via digital therapeutics were among the topics discussed at December’s events. Part of MINDCURE’s philosophy is about investing in the moment, and MINDCURE’s moment focuses on the psychedelic and digital therapeutics markets. The company reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that 12,472 registered mental health treatment facilities could benefit from the company’s proprietary digital therapeutics technology, iSTRYM.
The minimum viable product version of iSTRYM was so far made available to 20 ketamine clinics in nine different states in the U.S. and three Canadian provinces, and the company plans to launch full commercial deployment in Q1 or Q2 next year and to enter the European market later in 2022.
As member of the Digital Therapeutics Alliance with a dedicated product that is already being used successfully, MINDCURE has a prominent position in the global digital therapeutics market. This market is currently valued at $3.4 billion, according to 2021 figures. The market is projected to reach $13.1 billion by 2026, growing at a CAGR of 31.4%. This growth is being facilitated by the need to control healthcare costs and the rising focus on preventative healthcare options (
https://ibn.fm/mE4wv).
For more information, visit the company’s website at
www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at
http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the
InvestorBrandNetwork.